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Recognition  of  the  acute  and  chronic  burden  of respiratory  syncytial  virus  (RSV)  lower  respiratory  tract
infections  (LRTI)  sparked  a wave  of initiatives  to  develop  preventive  and  therapeutic  products  against
the  pathogen  in recent  years.  RSV  is  a leading  cause  of  hospitalization  in  infants  in  industrialized  and
developing  countries,  has  been  causally  linked  to recurrent  wheezing  during  childhood,  associated  withaccines
nfant mortality
ecurrent wheezing
nhanced respiratory syncytial virus
isease
regnancy
pediatric  asthma,  and  is  an  important  cause  of  mortality  in the  ﬁrst months  of  life  in the  developing  world.
Signiﬁcant  changes  in  the  epidemiology,  clinical  manifestations,  and  severe  consequences  of  LRTI  may
emerge  in  the next  decade  with  the  advent  of  novel  preventive  strategies  against  RSV.  This  manuscript
outlines  some  of these  changes  and  discusses  potential  scenarios  based  on  the  current  literature  and
experiences  with  other  pathogens.
© 2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY licenseRespiratory syncytial virus (RSV) is the main cause of hospi-
alization in infants in industrialized and developing countries
1,2]. Millions of children are hospitalized and an estimated
6,000–199,000 die every year worldwide due to RSV disease
2]. In addition, the virus has been causally linked to recurrent
heezing and associated with pediatric asthma [3–5]. The only
icensed intervention to prevent severe RSV disease is the adminis-
ration of a neutralizing anti-RSV humanized monoclonal antibody
palivizumab®) in speciﬁc high-risk populations, including infants
orn prematurely and those with congenital heart disease [6]. But
ost and the need for recurrent administration hamper its use in
ll infants. No speciﬁc treatment is available for RSV infections
o date. Severe cases require supportive therapy, mainly oxygen
upplementation and, less frequently, ventilatory support.
Recognition of the acute and chronic burden of RSV lower
espiratory tract infections (LRTI) sparked a wave of initiatives to
evelop preventive and therapeutic products against the pathogen
n recent years. A promising strategy under evaluation to prevent
evere RSV disease is immunization of pregnant women against
he virus. Maternal immunization aims to elicit high levels of pro-
ective antibody in pregnant women, fostering transplacentally
cquired antibody-mediated protection in infants during the ﬁrst
onths of life [7–9]. Other promising approaches to RSV preven-
ion in infants are under study, including but not limited to passive
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prophylaxis with long-lived monoclonal antibodies against a neu-
tralizing epitope in the RSV fusion (F) protein and immunization
with recombinant live attenuated RSV vaccines [6,10–12]. In fact,
the potential beneﬁts of passive immunization with a long-lived
monoclonal antibody are supported by prior experience with
palivizumab in infants from high-risk groups [6].
The surge of old and novel approaches to prevent RSV sug-
gests that we  may  witness a signiﬁcant change in the landscape
of respiratory infections in the near future, if the main cause of
infant hospitalization worldwide is tamed. While the burden of
RSV disease may  decrease, predicting the magnitude of change
is premature. Yet, numerous important lessons will emerge from
this international effort. First, RSV is responsible for a signiﬁ-
cant proportion of infant hospitalizations worldwide [1,2]. Second,
decreasing its impact may  affect other acute and chronic conse-
quences of RSV infection, from secondary bacterial infections and
mortality to recurrent wheezing and asthma [2–5]. Finally, RSV
prevention may  inform about other factors inﬂuencing maternal-
infant health such as human milk protection and/or the acute and
long-term effects of respiratory illness during pregnancy [13–16].
This manuscript is an attempt to address questions that may
emerge during or after RSV prevention, using current knowledge
from the RSV literature and extrapolating from previous experi-
ences with other pathogens.
How likely are new vaccine strategies to elicit enhanced RSV disease
(ERD)? In 1966, a formalin-inactivated vaccine against RSV (FIRSV)
was administered to infants and young children in the United States
[17–20]. During the winter of 1967, immunized children infected
with RSV developed an enhanced form of RSV disease (ERD)
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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haracterized by severe wheezing and bronchopneumonia
17–20]; two vaccinated infants died as toddlers when contracting
SV [17]. The mechanism of illness of ERD has not been completely
lucidated, but three immune correlates are generally accepted to
dentify candidate RSV vaccines that may  prime for enhancement:
he presence of low avidity, non-protective antibodies [21,22]
nd the absence of RSV-speciﬁc cytotoxic T lymphocytes after
mmunization [23–25], coupled with a Th2 polarization of the
mmune response in the respiratory tract after RSV infection
17,26–28]. The presence of alveolitis in cotton rats also correlated
ith autopsy ﬁndings in children with ERD during 1967 [29]. All
hese manifestations are routinely elicited in murine models by
 variety of RSV vaccine antigens that are not processed in the
ytoplasm.
Fortunately, concerns for ERD are minimal in several lead-
ng approaches to RSV prophylaxis. For instance, immunization of
regnant women to protect infants through transplacental trans-
er of antibody will boost responses in women of childbearing
ge seropositive for the virus. No seropositive individual ever
eveloped ERD [17]. In fact, polyclonal antibody avidity against
SV in these women is improved throughout life by repetitive
nfections [22], preventing priming for low afﬁnity responses dur-
ng immunization (precisely the same mechanism that protected
eropositive infants and children from FIRSV in 1967). Moreover,
RD manifestations associated with an aberrant antibody response,
fter deposition of immune complexes and complement activation,
re mediated by the pathogenic effect of primed CD4+ T lympho-
ytes [30–32]. And primed T cells will not be elicited in infants after
aternal immunization. Similarly, new strategies to confer long-
tanding passive protection at birth using monoclonal antibodies
ould also rely strictly on antibody. And previous experiences with
alivizumab and motavizumab have a long track record of safety in
ulnerable infants [6]. Finally, infant intranasal immunization with
ive attenuated RSV vaccines (LAV) mimic  natural infection, and
fter extensive testing in early phase trials never associated with
RD in seronegative subjects [33].
Yet, the logarithmic increase in RSV vaccine candidates in pre-
linical and clinical development potentially targeted to naïve
nfants confronts the ﬁeld with new challenges. In addition to tra-
itional approaches to immunization, a surge of novel platforms
tresses the need for bona ﬁde biomarkers and animal models to
inimize the risk for ERD in this population. Replication-defective
ene-based single-cycle vectors [34,35]; virus-like particles (VLPs)
ith protective antigens [36–38]; subunit vaccines adjuvanted
ith various TLR agonists [39]; new formulations with the pre-
usion conformation of RSV F [40–44] and others, challenge our
urrent ERD models and may  alter our current enhanced disease
riteria. For example, vaccine replication may  be unnecessary to
revent priming for ERD in PAMP-adjuvanted vaccines, or stabi-
ized pre-fusion RSV F protein may  elicit protective antibodies of
igh afﬁnity.
Assessing safety in animal models will be critical for new for-
ulations, because ERD never occurred in children who were
eropositive for RSV before immunization with FIRSV [17–20].
herefore, evaluation of vaccine candidates in seropositive indi-
iduals will likely not offer any clues about risk for ERD, as it is
recisely naiveté what allowed the immune system to mount an
berrant response.
Consequently, animal models will play a fundamental role
n predicting ERD before novel RSV vaccines reach seronegative
nfants. In this context, evaluation of new candidates in more than
ne model is ideal, as even subtle differences in the vaccine-dosing
chedule, contaminants in vaccine preparations, and challenges
ith ERD reproducibility in large animal models can affect
nterpretation of results [45,46]. Therefore, evaluation of novel can-
idates in well-established murine models, like BALB/c mice and2015) 6473–6478
cotton rats, followed by testing in a large animal model may  be
necessary.
Therefore, while new platforms targeted for infant immuniza-
tion should beneﬁt from testing in animal models of ERD during
preclinical evaluation, maternal immunization, anti-RSV mono-
clonal antibodies and live attenuated vaccines present a theoretical
and practical record that mitigates concerns about ERD priming.
Can speciﬁc preventive strategies against RSV protect every infant?
Experience with protective drugs against RSV is limited. A licensed
prophylactic intervention widely available today is the intramuscu-
lar administration during the respiratory season of the monoclonal
antibody palivizumab to premature babies and those with cyan-
otic congenital heart disease [6,47]. The efﬁcacy of palivizumab was
initially evaluated in a placebo-controlled, randomized trial (RCT)
using as primary end point reduction in hospitalization attributable
to RSV LRTI [47,48]. Prophylaxis resulted in a 55% overall decrease
in the rate of RSV-related hospitalizations in premature babies [47].
Palivizumab protected against LRTI, but did not prevent viral repli-
cation in the upper respiratory tract [49]. With this in mind and
experience from other mucosal vaccines, a primary goal for mater-
nal immunization and passive transfer of antibody in term infants
is to achieve protective titers of antibody to prevent severe LRTI.
Protecting the upper airways seems challenging.
The reason why a number of severe RSV LRTI cases still occurred
despite palivizumab or RSV-IG administration during the RCT
remains unclear [47,48]. Failure rates were higher in infants with
bronchopulmonary dysplasia, suggesting a component of lower air-
ways reactivity during RSV upper respiratory tract infections [47].
Another explanation may  be that palivizumab failures reﬂected
infections in the last week of the monthly dosing cycle, when serum
antibody fell below protective levels. Yet, 89.5% of palivizumab fail-
ures in North American trials were in infants heterozygous for a
single nucleotide polymorphism in Asp299Gly of Toll-Like receptor
4 (from now, TLR4+/− infants) [50]. The rate of TLR4+/− individuals
in the North American population is 10.5% [51]. Therefore, it seems
logical to wonder what is peculiar about TLR4+/− infants during
RSV infection, who seem to develop severe LRTI despite passive
protection in the lungs (but not in the upper respiratory tract) with
anti-RSV antibody.
Two observational studies in TLR4+/− urban infants born at
term in Tel Aviv and Buenos Aires (and receiving no prophylaxis)
found them to have signiﬁcantly higher odds for severe RSV dis-
ease than wild type RSV-infected controls [52,53]. A notable 80%
of middle class TLR4+/− infants in Tel Aviv and >85% in Buenos
Aires required hospitalization when visiting pediatric clinics or
the emergency room with respiratory symptoms [52,53]. In fact,
a distinguishing characteristic of TLR4+/− urban infants was  their
propensity to mount a pathogenic T helper type 2 (Th2) response
during RSV infection leading to severe lung disease [53]. There-
fore, it is plausible to speculate that TLR4+/− infants (who constitute
∼10% of all infants in industrialized western societies [51]) may
respond “atopically” to RSV upper respiratory tract infections and
– as observed in premature babies with palivizumab [47] – wheeze
severely despite having protective antibody titers in the lungs.
Notably, a gene by environment interaction mediates the effects
of TLR4 on RSV disease [53]. TLR4+/− infants from poor neighbor-
hoods in developing countries, typically exposed to high levels of
environmental bacterial endotoxin (LPS), do not experience Th2
bias and have milder RSV disease than urban TLR4+/− babies liv-
ing in low LPS environments in industrialized nations [53]. In fact,
the polymorphism protects these infants in impoverished areas of
low-income countries from severe RSV LRTI [53].Therefore, efﬁcacy and subsequent effectiveness of preven-
tive strategies against RSV may depend in part on environmental
exposures, particularly those related to poverty and farming, and
TLR4+/− frequency in different regions of the world. Other genes
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ay  replicate this phenomenon to different degrees. Interestingly,
e can only wonder whether vaccine failures in the future may
resent a “different”, more atopic type of RSV disease than the
ne we support with oxygen and no medications in our emergency
ooms today. This group, and a second group of older infants and
oung children experiencing milder illness after protection wanes,
ay  change the face of pediatric RSV disease as we know it today.
Will half of severe viral LRTI “vanish” after RSV vaccines are admin-
stered worldwide? Ideally, the overall burden of severe LRTI caused
oday by RSV would disappear with an effective RSV vaccine.
owever, once the virus’ competitive abilities are weakened by
mmunization, other viruses may  replace it.
Recent data from a RCT in premature babies in the Netherlands
uggest that, upon prevention of RSV LRTI with palivizumab, other
espiratory viruses may  potentially replace part of the LRTI bur-
en [3]. Studying 429 infants born at a gestational age between
3 and 35 weeks, Blanken et al. [3] describe a reduction in RSV
RTI, but report no differences in the absolute number of respira-
ory episodes, similar number of non-wheezing episodes associated
ith high fever or dyspnea, and an apparent increase in the rates of
nfection caused by other respiratory viral pathogens in recipients
f palivizumab.
This potential replacement is puzzling, as most viruses do not
ypically colonize the upper respiratory tract (unlike bacteria).
 hypothetical explanation for these observations may  be that
nfants intermittently experience “windows of susceptibility” to
espiratory viruses that allow pathogens to cause disease. RSV out-
ompetes other viruses for the nasopharyngeal niche during early
indows. After immunization (as with palivizumab [3]), infectiv-
ty of RSV may  be “weakened” and other viruses may  replace it
ecoming more frequent agents of LRTI.
Therefore, although LRTI burden will decrease, some of the bur-
en caused today by RSV may  be elicited in the future by other viral
athogens.
Will there be an impact on the rates of frequent wheezing and
sthma? Despite potential replacement, not every viral infection
ay  have the same long-term consequences. RSV LRTI in infants
nd young children is associated with 25–80% greater subsequent
ates of recurrent wheezing and asthma compared to same age
hildren not experiencing severe RSV LRTI [3–5]. Some of these
SV LRTI affect infants genetically predisposed to develop asthma
t an older age [54], but epidemiological studies in term infants
3,4], animal models [54] and, in particular, recent interventional
tudies in premature babies [3,55,56], show that severe RSV LRTI
lso contribute to the inception of recurrent wheezing and poten-
ially asthma in children (at least in industrialized countries). In
act, enough evidence exists today to consider a potential role
or RSV vaccines in decreasing the burden of recurrent wheezing
y preventing severe RSV LRTI [3,55,56]. Remarkably, this long-
erm effect elicited by RSV may  be speciﬁc, as it does not seem
o be triggered by severe infections with other viral pathogens
3]. Consequently, in the event of viral replacement, a signiﬁcant
nd speciﬁc impact of RSV vaccines may  be to reduce recurrent
heezing episodes in infants and children.
Interestingly, maternal immunization and passive prophylaxis
gainst RSV may  also modulate the inception of asthma through a
econd, indirect pathway. In line with the overwhelming evidence
upporting the Hygiene Hypothesis [57,58], upper respiratory tract
nfections during early months of life have been shown to decrease
he rates of pediatric asthma and AHR [59]. And the current strate-
ies to protect young infants would prevent pathogenic RSV LRTI,
hile most likely allowing RSV URTI. We  can only wonder whetherhese runny noses will be beneﬁcial, particularly in urban infants
rom industrialized nations.
Therefore, an important secondary beneﬁt of RSV vaccines pro-
ecting the lungs may  be to decrease the rates of frequent wheezing2015) 6473–6478 6475
and pediatric asthma through direct antiviral and indirect effects
on pulmonary susceptibility and maturation of adaptive immunity.
Will we see a protective effect against mortality from the vaccines?
Undoubtedly, a critical beneﬁt expected from new preventive
strategies against RSV is a signiﬁcant reduction in infant mortality
due to ARI in developing countries. In 2005, at least 3.4 million chil-
dren were hospitalized due to RSV LRTI and 66,000–199,000 died as
a result of the illness [2]. Ninety-nine percent of deaths occurred in
developing countries [2]. In the developing world, given the impact
of pneumonia in infant mortality [60–62], countries with pneumo-
coccal immunization programs may  begin to recognize RSV as an
important cause of mortality in their populations.
However, understanding the burden of RSV mortality is difﬁcult.
In developed countries, under-recording may  hamper mortality
estimates [46]. But more importantly, and unlike in industrialized
countries [63], most fatalities caused by respiratory pathogens in
developing countries occur in regions with limited access to viral
testing or occur at home [64]. Moreover, obtaining a nasal swab
or a nasopharyngeal aspirate for viral identiﬁcation in critically ill
patients at the hospitals is understandably not prioritized by physi-
cians during acute illness. Therefore, unless a study is speciﬁcally
designed – in agreement with doctors responsible for intensive
and emergent care – to deﬁne the viral etiologies of life threat-
ening and fatal infections, it will likely signiﬁcantly underestimate
the burden of RSV hospital-based mortality. To add to this limita-
tion, infants at home can die with RSV LRTI (undiagnosed), simply
exhausted from battling indolent respiratory distress due to lack
of medical care or oxygen supplementation. In many developing
countries, the number of home deaths during the respiratory sea-
son signiﬁcantly outnumbers hospital deaths, while replicating the
same seasonal pattern [2]. Given all these challenges, practition-
ers and public health ofﬁcials may  underestimate RSV virulence in
underserved populations due to the limited available data.
Preemptively identifying those individual families at high risk
for experiencing a home fatality in the event of infection within
these large vulnerable groups may  prove extremely challenging.
Factors inﬂuencing outcome may  range from health care seeking
behaviors, biological (e.g., birth weight, age) or social vulnerabilities
(e.g., single mother with many children, limited social network in
the neighborhood) to poor recognition of disease progression or
lack of/excessive trust on the medical system (cases in Argentina
frequently had a previous visit to the clinic, and remained reassured
at home even after unfavorable changes in clinical status).
Therefore, individualized prevention through strengthening of
health care systems should be a long-term goal with vast future
beneﬁcial implications for developing countries. Today, a preven-
tive intervention against the virus appears to be the best approach
to decrease hospital and home mortality due to RSV in the develop-
ing world. These beneﬁts may  be best appreciated in post-licensure
studies, as vaccines trials may  enhance surveillance and standard-
ize care, improving survival in all participants.
Will breastfeeding confer passive protection through RSV-speciﬁc
soluble IgA after vaccination? Breast milk is the single most impor-
tant intervention protecting infants against respiratory viruses
in developing countries to date [13,65]. While numerous passive
mechanisms of protection have been postulated, mucosal coating
with sIgA is the most widely accepted theory explaining human
milk protection [66,67]. However, this hypothesis has important
inconsistencies that require further consideration. First, protec-
tion would require recurrent “mini” gastric aspirations to coat the
nasopharynx, as the predicted persistence of molecules in the upper
respiratory tract is short lived [68]. This mechanism seems highly
inefﬁcient, not withstanding the considerable, recurrent risk for a
more severe aspiration. Second, the source of RSV in infant infec-
tions is most frequently a sibling [69]. Therefore, babies are exposed
to the virus simultaneously with their mothers [69]. Passive
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ntibody protection through milk would then require instanta-
eous boosting of maternal immunity to prevent infection in
nfants. After all, mothers cannot have protection available in ade-
uate concentrations against all pathogens at all times. But boosting
ould require a few days, sufﬁcient to transform prophylaxis into
reatment. And treatment with antibodies has been tested and
ailed against RSV [49]. Third, early studies on RSV and nasal IgA
howed a lack of correlation between baseline IgA levels and ARI
70,71], poor correlation between neutralizing activity and anti-
SV IgA levels [72,73], and frequent detection of non-neutralizing
nti-RSV IgA in nasal secretions [72]. Finally, numerous studies
bserved a signiﬁcant gender bias in human milk prevention of
evere viral LRTI in babies [14,74–76]. In all these studies, milk
rotected girls better than boys. These observations strongly sug-
est that breast milk primary protective effects are not conferred
y passive transfer of a soluble molecule, like sIgA (which would,
ost likely, be gender indifferent). Instead, human milk appears to
ctivate a process in the baby. And this process is better activated
n females [14,74–76].
Interestingly, human milk can strongly protect a very low birth
eight female against viral respiratory pathogens. Apparently, this
rocess stems from activation of internal protective mechanisms,
n girls better than in boys. But these premature babies have no
mmune memory of previous viral exposures. Therefore, the main
rotective effect of human milk against respiratory viruses, RSV
ncluded, is likely not dependent on adaptive immunity. We  have
pent ﬁfty years searching for vaccines against individual respira-
ory viruses. Nature may  have ﬁgured out a way to prevent them
ll through a different, and perhaps single strategy. It remains to
e seen whether such beneﬁts can be boosted through RSV immu-
ization.
Will other beneﬁts for mother and baby derive from maternal
mmunization? Notably, a series of important additional questions
ay  be answered during and after maternal immunization tri-
ls. First, as described for inﬂuenza [15,77], maternal vaccination
gainst RSV may  protect an undetermined number of babies against
remature birth or low birth weight. Second, the burden of RSV dis-
ase during pregnancy is unknown. Immunization will contribute
o deﬁne the magnitude of this problem, and may  result in inadver-
ent additional beneﬁts like fewer sick days or decreased antibiotic
se in pregnant women. Finally, whether severe and/or prolonged
ypoxemia during RSV LRTI can have neurodevelopmental conse-
uences in young infants is also unknown.
Maternal immunization against RSV represents an opportunity
o explore the impact of this pathogen in pregnant women and its
econdary effects on the newborn baby. Exploratory neurodevelop-
ental studies in infants with varying degrees of severity during
rimary RSV infection in low income countries may  allow a bet-
er estimation of whether neurodevelopmental beneﬁts may  result
rom prevention of severe RSV disease.
Are there speciﬁc challenges for these vaccine strategies? Beyond
he questions outlined above, each of these approaches faces indi-
idual challenges that merit consideration (beyond the speciﬁc
valuation of potential side effects associated with individual prod-
cts [78,79]). Maternal immunization, most likely using a variety of
reparations including pre or post-fusion F, will have to boost anti-
ody responses in pregnant women to transfer babies adequate
rotection for several months. Therefore, depending on the kinet-
cs and magnitude of the response elicited by each preparation,
iming of immunization may  differ. In addition, pre-existent anti-
odies against pre or post-F in women may  affect responses [80].
ther poorly characterized factors may  inﬂuence antibody decayn infants in developing countries [81]; and the extent and qual-
ty of prenatal care, and acceptance of maternal immunization in
ifferent populations may  inﬂuence vaccination rates [82,83]. Pas-
ive prophylaxis may  allow direct inoculation of babies at birth
[2015) 6473–6478
before and during the RSV season, a period that is easier to deﬁne
in regions with well-deﬁned winters, but potentially challenging
to delineate in advance in tropical climates [84]. And cost will be
a critical factor determining its viability as a public health inter-
vention [85]. Finally, intranasal live attenuated vaccines may  be
administered once maternal or passive antibody protection wanes,
extending protection through the ﬁrst year of life. But these prepa-
rations will require sufﬁcient stability for tropical climates, and will
use a novel route of immunization, particularly for the developing
world (where intranasal live attenuated inﬂuenza vaccines are not
available).
In summary, the landscape of acute respiratory illness may
change through RSV vaccination. In the footsteps of H. inﬂuenzae
type B and pneumococcal vaccines, prevention of RSV may once
again alter the microbiology of lung diseases in infants and young
children. The speciﬁc implications of these interventions will be
revealed during the next decade, and will deﬁne a new set of goals
and questions for future programs.
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